

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Özlem TÜRECI, *et al.*)
Application No. 10/575,640) Art Group: Not Yet Assigned
Filed: April 13, 2006) Examiner: Not Yet Assigned
For: RECOMBINANT VACCINES AND)
USE THEREOF) Attorney Docket No.: VOS-120

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This document is in response to the Notification of Defective Response dated September 25, 2007 in the above identified application.

Submitted herewith are:

- A. A paper copy and Computer Readable Form (CRF) of a Replacement Sequence Listing, as requested in the Notification;
- B. A Statement Under 37 C.F.R. 1.821(f);
- C. A copy of the Notification; and
- D. An Amendment to the specification requesting that the Replacement Sequence Listing be entered.


No fees are deemed to be due at this time, however, the Commissioner is hereby authorized to charge any additional fees that may be due to our Deposit Account No. 15-0508.

Respectfully submitted,

Dated:

18 Oct 2007

By:


Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/575,640	FIRST NAMED APPLICANT Özlem Türeç	ATTY. DOCKET NO. VOS120
---	--------------------------------------	----------------------------

2387
 OLSON & HIERL, LTD.
 20 NORTH WACKER DRIVE
 36TH FLOOR
 CHICAGO, IL 60606

RECEIVED

SEP 28 2007

OLSON & HIERL, LTD

To be
Docket

INTERNATIONAL APPLICATION NO.

PCT/EP04/11512

I.A. FILING DATE

10/13/2004

PRIORITY DATE



10/14/2003

CONFIRMATION NO. 4630

371 FORMALITIES LETTER



OC00000025991395



Date Mailed: 09/25/2007

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- o Indication of Small Entity Status
- o Priority Document
- o Copy of the International Application filed on 04/13/2006
- o English Translation of the IA filed on 04/13/2006
- o Copy of the International Search Report filed on 04/13/2006
- o Preliminary Amendments filed on 04/13/2006
- o Biochemical Sequence Diskette filed on 02/09/2007
- o Oath or Declaration filed on 02/09/2007
- o Small Entity Statement filed on 04/13/2006
- o U.S. Basic National Fees filed on 04/13/2006
- o Priority Documents filed on 04/13/2006
- o Specification filed on 04/13/2006
- o Claims filed on 04/13/2006
- o Abstracts filed on 04/13/2006
- o Drawings filed on 04/13/2006
- o Paper nucleotide sequence listings filed on 04/13/2006

Applicant's response filed 02/09/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 12/12/2006 have not been completed.

- o This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in

computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- o A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- o For Rules Interpretation, call (571) 272-0951
- o For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- o Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/575,640	PCT/EP04/11512	VOS120

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Thu Sep 06 16:59:15 EDT 2007

=====

Reviewer Comments:

<110> TŞRECI, TMzlem
SAHIN, Ugar
KREITER, Sebastian
Johannes Gutenberg-Universit,t Mainz, vertreten durch den
Pr,,sidenten

Please remove all foreign accent marks: they are non-ASCII characters, and cannot be processed.

<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Enzyme restriction site

Please try to clarify the above <223> response: can the source of the genetic material be mentioned? This type of response appears in Sequence 8.

<210> 11
<211> 1962
<212> DNA
<213> Artificial Sequence

<220>
<223> Nucleic acid encoding a fusion protein

The above <223> response needs clarification: what are the sources of the fusion protein? This type of response appears in Sequence 13, too.
